INGELHEIM, Germany--(BUSINESS WIRE)--The Boehringer Ingelheim and EFSD diabetes partnership has opened submissions for diabetes research grant applications from across Europe. In a collaboration which aims to stimulate and accelerate European research in diabetes, the EFSD/Boehringer Ingelheim European Diabetes Research Programmes have dedicated more than 2.5 million euros over three years to support research projects targeting specific areas of interest. “Diabetes affects more than 371 million people worldwide and diabetes remains undiagnosed in up to 50% of cases,” said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. “We are delighted to partner with the EFSD on this initiative and hope the grant encourages and supports new research in the field of diabetes.”
